Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Condition(s):Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell LymphomaLast Updated:March 19, 2018Terminated
Hide Studies Not Open or Pending
Condition(s):Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell LymphomaLast Updated:March 19, 2018Terminated
Condition(s):Lymphoma, Large Cell, Diffuse; Lymphoma, Mixed Cell, Diffuse; Primary Mediastinal Large B-Cell LymphomaLast Updated:September 12, 2014Completed
Condition(s):Multiple MyelomaLast Updated:January 27, 2023Terminated
Condition(s):LymphomaLast Updated:June 3, 2016Completed
Condition(s):Primary Hepatocellular CarcinomaLast Updated:October 23, 2012Terminated
Condition(s):Chronic Hepatitis CLast Updated:August 29, 2014Terminated
Condition(s):Melanoma; Malignant MelanomaLast Updated:January 21, 2016Completed
Condition(s):Metastatic Colorectal CancerLast Updated:July 8, 2015Completed
Condition(s):Renal Cell CarcinomaLast Updated:February 8, 2017Terminated
Condition(s):DIPGLast Updated:September 13, 2016Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.